## Ferric Carboxymaltose (Injectafer) Order Form

SOMC Cancer Center & Infusion Ph: (740) 356-7490

Fx: (740) 356-7488

P	ATIENT & PRESC	RIBER INFORMA	TION		
Patient Name:	DOB:	Phone: (H	)	(C)	
Patient Address:			,		
Ht.: □lbs. □kg.					
Prescriber Name/Title:	A	ddress:			
Phone: Fax:		Prescriber NPI #:			
REQUIRED: Most Recent H&P, clinical notes, he required unless the patient is established with intolerance, outcomes, or contraindications to	SOMC. Supporting	clinical notes shoul		• •	
DIAGNOSIS, CLINICAL INFORMATION, & PRESCRIPTION					
☑ Infusion rates will follow manufacturer recom	mendations.				
☑ In the event of an adverse reaction, line maintenance/flushes, or O2 are required, the SOMC AIC established protocols will be utilized.					
☑ 0.9% NaCl 250 ml primary at KVO during infusion, and flush line during observation period.					
☑ Monitor for any adverse events post administ	ration for at least 30	minutes or until clin	ically stable.		
Pre-Treatment Medications: (None Required ☐ Diphenhydramine (Benadryl) 25 mg PO 1x c ☐ Diphenhydramine (Benadryl) 12.5 mg IV 1x ☐ Other (Please Specify)	dose dose	d 30 minutes prior t	o each administr	ation.	
		AND —			
Diagnosis (Check all that apply)  ☐ Iron Deficiency Anemia with unsatisfactory ☐ Iron Deficiency Anemia in non-dialysis depe ☐ Iron deficiency in adult patients with heart fai ☐ Other	endent chronic kidne lure and New York H	ey disease. eart Association class	•	exercise capacity.	
(Please Specify Stage in CKD)					
Dose:  ☐ Ferric carboxymaltose (Injectafer) 750 m ☐ Ferric carboxymaltose (Injectafer) 15 mg 1000/mg		OR —			
PRO	OVIDER: DATE:	TIME:	SIGNATURE:		



P & T Comm.		
11/14/23		
11/14/25		
V11142023.0		